viewNoxopharm Ltd

Noxopharm Ltd debuts on ASX; supported by solid trading volumes


Noxopharm Ltd (ASX:NOX), an Australian biotech company, listed on the ASX today after raising $6 million in an over-subscribed IPO.

The clinic-ready company is focused on commencing the first human clinical trial for its drug, NOX66.

The purpose of NOX66 is to eliminate the ability of a cancer cell to develop and maintain its drug-resistance mechanisms, something that leads to many cancer patients eventually running out of treatment options.

Graham Kelly, CEO, held various senior roles for nearly 20 years at Novogen, a $1+ billion company. Novogen attempted to develop an anti-cancer drug targeting a similar market.

At 3:00PM Sydney time, over 5 million Noxopharm shares had been traded on the ASX.

Shares issued under the IPO were priced at $0.20 and shares have traded between $0.18 and $0.20 today.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

Quick facts: Noxopharm Ltd

Price: 0.4 AUD

Market: ASX
Market Cap: $85.3 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


David Lenigas reckons Greatland Gold's Havieron is 'once in a generation' find

David Lenigas discusses Greatland Gold (LON:GGP) after the company pushed through £1bn market capitalisation last week. Australian gold major Newcrest Mining (ASX:NCM) has a farm-in agreement with GGP to explore and develop the Havieron gold-copper project and earn 70% interest in the 12...

15 hours, 54 minutes ago

2 min read